Cancer cells: They're masters of disguise, and their latest trick involves a dangerous DNA repair strategy. Our DNA is constantly under attack, with double-strand breaks being one of the most threatening types of damage. These occur when both strands of the DNA helix are severed simultaneously. Healthy cells have highly accurate repair systems to fix this, but what happens when those systems fail? Scientists at Scripps Research have uncovered a fascinating backup plan cancer cells use to survive. This discovery could be the key to new cancer treatments. But here's where it gets controversial: this survival strategy could be turned against the tumors that rely on it!
The RNA-DNA Tango: A Recipe for Genomic Instability. The study, published in Cell Reports, focused on a protein that untangles twisted genetic material. This includes structures called R-loops, which are RNA-DNA tangles that disrupt normal DNA function. Imagine a tangled mess where newly produced RNA fails to separate from the DNA, leaving one side exposed and vulnerable.
"R-loops are crucial for many cellular functions, but they must be tightly controlled," explains senior author Xiaohua Wu, a professor at Scripps Research. "If not regulated, they can accumulate to harmful levels and cause genome instability."
The Role of SETX: A Link Between Cancer and Neurological Diseases. The researchers investigated a helicase protein called senataxin (SETX), which unwinds tangled genetic material. Mutations in the SETX gene are linked to rare neurological disorders like ataxia and amyotrophic lateral sclerosis (ALS). Interestingly, these same mutations also appear in certain cancers, including uterine, skin, and breast cancers. This connection raised a critical question: How do cancer cells cope with the stress caused by excessive R-loops when SETX is missing or defective?
A Cellular Crisis: Triggering Emergency Repair. To find answers, Wu's team studied cells lacking SETX, which showed unusually high levels of R-loops. They then observed what happened when double-strand breaks formed at these tangled sites. The cells accumulated significant DNA damage, as expected. But what surprised the researchers was the aggressive response of the cells.
"We were surprised but excited to find that the cell turns on an emergency DNA repair mechanism called break-induced replication (BIR)," says Wu.
Break-Induced Replication: The Backup System. Under normal circumstances, BIR helps rescue stalled DNA replication forks. It can also act as a fallback option for double-strand breaks. Instead of making small, precise fixes, BIR copies long stretches of DNA to reconnect broken pieces. This allows cells to survive severe damage, but it comes at a cost.
"It's like an emergency repair team that works intensively but makes more mistakes," says Wu.
The researchers discovered that without SETX, R-loops accumulate directly at DNA breaks. This buildup interferes with the cell's usual repair signals. As a result, the broken DNA ends are trimmed excessively, exposing long sections of single-stranded DNA. These exposed regions attract the BIR machinery, including PIF1, a helicase essential for BIR to operate. Together, the exposed DNA and PIF1 trigger the BIR repair process.
A Survival Advantage: Creating a Weakness. Although BIR is prone to errors, it allows SETX-deficient cells to survive. However, over time, these cells become dependent on BIR to repair DNA damage. If this repair route is blocked, the cells lose their ability to fix double-strand breaks and die. This vulnerability is known as synthetic lethality, a principle already used in several targeted cancer treatments.
Wu's team found that SETX-deficient cells are especially reliant on three BIR-related proteins: PIF1, RAD52, and XPF.
"What's important is that these aren't essential in normal cells, which means we could selectively kill SETX-deficient tumors," says Wu.
From Discovery to Potential Therapy. While the findings point to a promising strategy, clinical applications will take time.
"We're now exploring ways to inhibit these BIR factors, trying to find ones with the right activity and low toxicity," she adds.
The team is also investigating which cancers accumulate the highest levels of R-loops and under what conditions. Identifying tumors most likely to respond to BIR-targeted therapies will be a key next step.
Beyond SETX: Broader Implications. Although SETX deficiency itself is relatively rare, many cancers build up R-loops through other pathways, including oncogene activation or hormone signaling such as estrogen in certain breast cancers. This means the approach could be relevant to a much broader range of tumors, not only those with SETX mutations.
In addition to Wu, authors of the study "Break-induced replication is activated to repair R-loop-associated double-strand breaks in SETX-deficient cells" include Tong Wu, Youhang Li, Yuqin Zhao and Sameer Bikram Shah of Scripps Research; and Linda Z. Shi of the University of California San Diego.
This work was supported by the National Institutes of Health (grants GM141868, CA294646, CA244912 and CA187052).
What do you think? Could targeting BIR be a game-changer in cancer treatment? Do you have any questions about this research? Share your thoughts in the comments below!
